Clinical Trial: Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117409) titled 'Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure' on Aug. 05.

Brief Summary: This is an observational, retrospective, multicenter study aimed to compare the toxicity of Nivolumab in patients with metastatic renal cell carcinoma treated in line II and III stratified into 3 patient groups:

* patients with normal or mildly reduced renal function (GFR=60 ml/min/1.73 m^2);

* patients with moderate renal impairment (GFR =30 ml/min/1.73 m^2),

* patients with severe renal impairment (GFR =15 ml/min/1.73 m^2) Patients must have been treated with Nivolumab, as per clinical practice. All patients who ha...